Advertisement

New Trends for Treatment in Multiple Sclerosis

  • R. E. Gonsette
Conference paper

Abstract

The 1980s will probably remain the decade of a worldwide concern in multiple sclerosis (MS) therapy. Indeed a better understanding of immune mechanisms associated with the development of CNS lesions have rekindled the interest for basic treatments capable of influencing the progression of the disease.

Keywords

Multiple Sclerosis Myelin Basic Protein Lymphocyte Subset Experimental Allergic Encephalomyelitis Annual Relapse Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lees J, Hauville C, Lenormand B, Samson M, Sauger F, Maitrot B, Monconduit M, Coquerel A (1986) Immimomodulation in multiple sclerosis: clinical and biological correlations. Joint meeting of the Gesellschaft fur Immunologie and the Société Français d’Immunologie, Strasbourg, 20–22 Nov.Google Scholar
  2. 2.
    Aimard JP, Witz F, Conroy T, Lederlin P, Humbert JC, Barroche G, Streiff F (1985) Leucémie aiguë secondaire au traitement de la sclérose en plaque par le Chlorambucil. Rev Neurol 141: 152–154Google Scholar
  3. 3.
    Patzold U (1985) Long-term treatment of Azathioprine in multiple sclerosis. Results of a controlled follow-up study. In: International MS conference. Europ Neurol 24:434–435Google Scholar
  4. 4.
    Kappos L (1986) Cyclosporine A in the medical treatment of multiple sclerosis and myasthenia. Joint meeting of the German Neurological Society and the Neurological Societies of the Benelux Countries, Aachen 17–20 Sept.Google Scholar
  5. 5.
    Gonsette RE, Demonty L, Delmotte Y (1977) Intensive immunosuppression with Cyclophosphamide in multiple slcerosis: a follow-up of 110 patients for 2-6 years. J Neurol 214: 173–181PubMedCrossRefGoogle Scholar
  6. 6.
    Hommes OR, Lamers KJB, Reekers R (1980) Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis. J Neurol 223:177–190CrossRefGoogle Scholar
  7. 7.
    Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, Mills JA, Weinier HL (1983) Intensive immunosuppression in progressive multiple slcerosis. A randomized, three-arm study of high-dose intravenous Cyclophosphamide, plasma exchange, and ACTH. A Engl J Med 308:173–180Google Scholar
  8. 8.
    Gonsette RE (1985) Combined acute and chronic immunotherapy with Cyclophosphamide (Endoxan) in multiple sclerosis. In: International MS conference. Europ Neurol 24:437Google Scholar
  9. 9.
    Brinkman CJ, Nillesen WM, Hommes OR (1983) T-cell subpopulations in blood and cerebrospinal fluid of multiple sclerosis patients: effect of Cyclophosphamide. Clin Immunol Immunopath 29:341-348CrossRefGoogle Scholar
  10. 10.
    Bania MB, Antel JP, Reder AT, Nicholas MK, Arnason BGW (1986) Suppressor and cytolytic cell function in multiple sclerosis. Effects of Cyclosporine A and Interleukin 2. J Clin Invest 78: 582–586Google Scholar
  11. 11.
    Bornstein MB, Miller A, Slagle S et al. (1987) Copolymer I in exacerbating-remitting multiple sclerosis. J Engl J Med 317:408–414CrossRefGoogle Scholar
  12. 12.
    Pompidou A, Rancurel G, Delsauw MC, Telvi L, Cour V, Buge A (1986) Amélioration clinique et immunologique des scléroses en plaques à forme rémittente par l’isoprinosine. Etude pilote randomisée. Presse Médicale 15:930–931Google Scholar
  13. 13.
    Caltagirone C, Carlesimo A (1986) Methisoprinol in the treatment of multiple sclerosis. A pilot study. Acta Neurol Scan 74:293–296CrossRefGoogle Scholar
  14. 14.
    Cook SD, Devereux C, Troiano R, Hafstein MP, Zito G, Hernandez E, Lavenhar M, Vidaver R, Dowling PC (1986) Effect of total lymphoid irradiation in chronic progressive multiple sclerosis. Lancet 1:1405–1409PubMedCrossRefGoogle Scholar
  15. 15.
    Kolar OJ, Hornback NB (1986) Total lymphoid irradiation in multiple sclerosis. Lancet: 453Google Scholar
  16. 16.
    Jacobs L, O’Malley JA, Freeman A, Ekes R, Reese PA (1985) Intrathecal interferon in the treatment of multiple sclerosis. Patient follow-up. Arch Neurol 42:841–847Google Scholar
  17. 17.
    Camenga DL, Johnson KP, Alter M, Engelhardt CD, Fishman PS, Greenstein JI, Haley AS, Hirsch RL, Kleiner JE, Kofie VY, Koski CL, Margulies SL, Panitch HS, Valero R (1986) Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis. Arch Neurol 43:1239–1246PubMedGoogle Scholar
  18. 18.
    Panitch HS (1987) Systemic alpha-Interferon in multiple sclerosis. Long-term patient follow-up. Arch Neurol 44:61–63Google Scholar
  19. 19.
    Panitch HS, Haley AS, Hirsch RL, Johnson KP (1986) A trial of gamma Interferon in multiple sclerosis: clinical results. Neurol 36 [suppl]:285Google Scholar
  20. 20.
    Bever CT, Salazar AM, Neely E, Ferraraccio BE, Rose JW, McFArland HF, Levy HB, McFarlin DE (1986) Preliminary trial of poly ICLC in chronic progressive multiple sclerosis. Neurology 366:494–498Google Scholar
  21. 21.
    Ridge SC, Sloboda AE, McReynolds RA, Levine S, Oronsky AL, Kerwar SS (1985) Suppression of experimental allergic encephalomyelitis by Mitoxantrone. Clin Immunol Immunopathol 35:35–42PubMedCrossRefGoogle Scholar
  22. 22.
    Levine S, Saltzman A (1986) Regional suppression therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by Mitoxantrone. J Neuroimmunol 13:175–181PubMedCrossRefGoogle Scholar
  23. 23.
    Bicker U, Friedberg KD, Isert B, Mengel K (1984) Comparative investigations of various immunoregulatory substances in the delayed type hypersensitivity test of the mouse. J Immunopharm 6: 57–67CrossRefGoogle Scholar
  24. 24.
    Sedgwick JD, Mason DW (1986) The mechanism of inhibition of experimental allergic encephalomyelitis in the rat by monoclonal antibody against CD4. J Neuroimmunol 13:217–232PubMedCrossRefGoogle Scholar
  25. 25.
    Hafier DA, Fallis RJ, Dawson DM, Schlossman SF, Reinherz EL, Weiner HL (1985) Pilot study of anti-pan-T-cell monoclonal antibodies for the treatment of progressive multiple sclerosis. Neurol 35 [suppl]: 103Google Scholar
  26. 26.
    Rose LM, Ginsberg AH, Rothstein TL, Ledbetter JA, Clark EA (1985) Selective loss of a subset of D helper cells in active multiple sclerosis. Proc Natl Acad Sci 82:7389–7393PubMedCrossRefGoogle Scholar
  27. 27.
    Morimoto C, Hafier DA, Weiner HL, Letvin NL, Hagan M, Daley J, Schlossman SF (1987) Selective loss of the suppressor-inducer T-cell subset in progressive multiple sclerosis. Analysis with anti-2H4 monoclonal antibody. J Engl J Med 316:67–72Google Scholar
  28. 28.
    Van Lambalgen R (1986) An automated method for the detection of lymphocyte subset specific antibodies in multiple sclerosis sera. J Immunol Meth 89:117–121CrossRefGoogle Scholar
  29. 29.
    Bowern N, Ramshaw IA, Clark IA, Doherty PC (1984) Inhibiton of autoimmune neuropathological process by treatment with an iron-chelating agent. J Exp Med 160:1532–1543PubMedCrossRefGoogle Scholar
  30. 30.
    Brosnan CF, Goldmuntz EA, Cammer W, Factor SM, Bloom BR, Norton WT (1985) Prazosin, an alpha 1-adrenaergic receptor antagonist, suppresses experimental autoimmune encephalomyelitis in the Lewis rat. Proc Natl Acad Sci 82:5915–5919PubMedCrossRefGoogle Scholar
  31. 31.
    Fujinami RS, Oldstone MBA (1985) Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 30: 1043–1045CrossRefGoogle Scholar
  32. 32.
    Steinman L (1986) Molecular approaches towards a therapy for multiple sclerosis. International symposium on multiple sclerosis, Rome, 16–18 Oct 1986 Short CommunicationsGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • R. E. Gonsette
    • 1
  1. 1.Belgian National Center for Multiple SclerosisMelsbroekBelgium

Personalised recommendations